Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment.
Muniz, Miguel, Mahmoud, Ahmed , Orme, Jacob J. , Kwon, John Y. , Andrews, Jack R. , Kase, Adam M. , Ravi, Praful , Kwon, Eugene D., Mahmoud, Ahmed M , Sartor, Oliver , Kwon, John Y., Mosalem, Osama , Bryce, Alan H. , Riaz, Irbaz Bin , Thorpe, Matthew , Kendi, A. Tuba , Johnson, Geoffrey B. , Childs, Daniel S.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 175-175

10.1200/jco.2024.42.4_suppl.175 Get It

175 Background: It is well-known that patients with liver metastases from metastatic castration resistant prostate cancer (mCRPC) have poorer or transient responses to many forms of systemic therapy. Data on outcomes following treatment with Lutetium-177–PSMA-617 is scarce. The VISION trial reports hazard ratios for overall survival in the subgroup of patients with liver metastases without disclosing the absolute duration of survival. Using real-world clinical data, we examine this important subgroup of patients, describing their PSA response rates and survival. Methods: A single institution database was assembled to include all patients receiving 177-Lu-PSMA-617 at Mayo Clinic Rochester, MN, and starting treatment in the interval of March 2022 to March 2023. Baseline clinicopathologic and imaging characteristics were abstracted. Patients were categorized based on the presence or absence of measurable liver metastases on their baseline PSMA PET scan. Best PSA response while on treatment was annotated and reported as percent decline from baseline. Survival was calculated from date of first cycle of 177-Lu-PSMA-617. PSA50 response and overall survival (OS) outcomes for the two groups (liver metastases versus no liver metastases) were compared using Chi square test and Kaplan-Meier method, respectively. Those with available pre-treatment circulating tumor DNA (ctDNA) genomic profiling, performed by Guardant (83 gene panel), were assessed for the presence of pathogenic and likely pathogenic alterations. Findings are summarized using descriptive statistics. Results: The overall cohort consisted of 212 patients, including 29 (14%) with liver metastases on pre-treatment PSMA PET/CT. The median number of cycles received was 4 (range, 1-6) for patients with liver metastases and 6 (range, 1-6) for those without hepatic involvement. The observed PSA50 response trended lower for those with liver metastases (34.5% [10/29] versus 51% [94/183], p= 0.091). At median (IQR) follow-up of 10 (8-12) months, there was a numerical but not statistically significant difference in median OS (11.28 months versus NR, p=0.066). In the exploratory analysis of baseline ctDNA, BRCA2 copy number loss was relatively enriched among patients with liver metastases (4 of 19, 21%) versus patients without liver disease (5.7%, 9/158). Conclusions: Our data suggest that the presence of liver metastases predict poorer outcomes in patients receiving Lutetium-177–PSMA-617 treatment, which is similar to data reported with other forms of systemic therapy for mCRPC. To maximize the anti-tumor activity of radioligand therapy in the liver, combination approaches should be explored.
Building Authentic Connection in the Patient-Physician Relationship
Fuehrer, Sheryl, Weil, Amy , Osterberg, Lars , Meunier, Matthew R. , Schwartz, Rachel , Schwartz, Rachel , Zulman, Donna M.

Mayo Clinic

Journal of Primary Care & Community Health | January 28, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319231225996 | PMID 38281122 Get It

Introduction/Objectives: Delivering optimal patient care is impacted by a physician’s ability to build trusting relationships with patients. Identifying techniques for rapport building is important for promoting patient-physician collaboration and improved patient outcomes. This study sought to characterize the approaches highly skilled primary care physicians (PCPs) use to effectively connect with diverse patients. Methods: Using an inductive thematic analysis approach, we analyzed semi-structured interview transcripts with 10 PCPs identified by leadership and/or colleagues for having exceptional patient communication skills. PCPs practiced in 3 diverse clinic settings: (1) academic medical center, (2) Veterans Affairs clinic, and (3) safety-net community clinic. Results and Conclusions: The thematic analysis yielded 5 themes that enable physicians to establish connections with patients: Respect for the Patient, Engaged Curiosity, Focused Listening, Mutual Participation, and Self-Awareness. Underlying all of these themes was a quality of authenticity, or a state of symmetry between one’s internal experience and external words and actions. Adopting these communication techniques while allowing for adaptability in order to remain authentic in one’s interactions with patients may facilitate improved connection and trust with patients. Encouraging physician authenticity in the patient-physician relationship supports a shift toward relationship-centered care. Additional medical education training is needed to facilitate authentic connection between physicians and patients.
Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper
Perucca, Emilio , French, Jacqueline A. , Aljandeel, Ghaieb , Balestrini, Simona , Braga, Patrícia , Burneo, Jorge G. , Charway‐Felli, Augustina , Cross, J. Helen , Galanopoulou, Aristea S. , Jain, Satish , Jiang, Yuwu , Kälviäinen, Reetta , Lim, Shih Hui , Meador, Kimford J. , Mogal, Zarine , Nabbout, Rima , Sofia, Francesca , Triki, Chahnez , Walker, Matthew C. , Wiebe, Samuel , Wilmshurst, Jo M. , Yacubian, Elza Márcia Targas , Kapur, Jaideep , Felli, Augustina Charway , Somerville, Ernest , Sperling, Michael R , Triki, Chahnez , Trinka, Eugen , Walker, Matthew C , Wiebe, Samuel , Wilmshurst, Jo M , Wirrell, Elaine C , Yacubian, Elza Márcia , Kapur, Jaideep , Galanopoulou, Aristea , Cross, Helen J , Perucca, Emilio , French, Jacqueline , Balestrini, Simona , Meador, Kimford J , Burneo, Jorge G , Jain, Satish , Somerville, Ernest , Sperling, Michael R. , Trinka, Eugen , Wirrell, Elaine

Mayo Clinic

Epilepsia | January 27, 2024 | Volume: 65 | Issue: 3 | Pages: 533-541

10.1111/epi.17877 | PMID 38279786 Get It

Abstract A variety of terms, such as “antiepileptic,” “anticonvulsant,” and “antiseizure” have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named “antiseizure medications”. This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term “antiseizure” to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having “antiepileptogenic” or “disease‐modifying” effects. A more‐refined terminology to describe precisely these actions needs to be developed.
Mis-spliced transcripts generate de novo proteins in TDP-43–related ALS/FTD
Seddighi, Sahba , Qi, Yue , Brown, Anna‐Leigh , Wilkins, Oscar G. , Bereda, Colleen , Belair, Cédric , Zhang, Yong‐Jie , Prudencio, Mercedes , Keuss, Matthew J. , Khandeshi, Aditya J , Pickles, Sarah , Hill, Sarah E. , Hawrot, James , Ramos, Daniel M. , Roberts, Jessica P. , Sacramento, Erika Kelmer , Shah, Syed Islamuddin , Nalls, Mike A., Colon, J , Reyes, Joel F. , Ryan, Veronica H. , Nelson, Matthew P. , Cook, Casey , Screven, Laurel A. , Kwan, Justin , Mehta, Puja R. , Zanovello, Matteo , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P. , Ahmed, Aisha , Ule, Jernej , Jacobson, Steven , Reich, Daniel S. , Rohrer, Jonathan D. , Malaspina, Andrea , Glass, Jonathan D. , Seyfried, Nicholas T., Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E. , Fratta, Pietro , Qi, Yue A , Khandeshi, Aditya , Yuan, Hebao , Roberts, Jessica , Sacramento, Erika Kelmer , Shah, Syed I , Colón-Mercado, Jennifer M , Reyes, Joel F , Ryan, Veronica H , Cook, Casey N , Li, Ziyi , Screven, Laurel , Mehta, Puja R , Zanovello, Matteo , Hallegger, Martina , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P , Duong, Duc M , Ahmed, Aisha , Secrier, Maria , Ule, Jernej , Jacobson, Steven , Reich, Daniel S , Rohrer, Jonathan D , Dickson, Dennis W , Glass, Jonathan D , Seyfried, Nicholas T , Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E , Zhang, Yong-Jie , Prudencio, Mercedes , Bereda, Colleen , Fratta, Pietro , Li, Ziyi , Dickson, Dennis W. , Ori‬‬, Alessandro , Seyfried, Nicholas T.

Mayo Clinic

Science Translational Medicine | January 26, 2024 | Volume: 16 | Issue: 734 | Pages: No page available

10.1126/scitranslmed.adg7162 | PMID 38277467 Get It

Functional loss of TDP-43, an RNA binding protein genetically and pathologically linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), leads to the inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons can promote the degradation of affected transcripts, deleteriously altering cellular function through loss-of-function mechanisms. Here, we show that mRNA transcripts harboring cryptic exons generated de novo proteins in TDP-43–depleted human iPSC–derived neurons in vitro, and de novo peptides were found in cerebrospinal fluid (CSF) samples from patients with ALS or FTD. Using coordinated transcriptomic and proteomic studies of TDP-43–depleted human iPSC–derived neurons, we identified 65 peptides that mapped to 12 cryptic exons. Cryptic exons identified in TDP-43–depleted human iPSC–derived neurons were predictive of cryptic exons expressed in postmortem brain tissue from patients with TDP-43 proteinopathy. These cryptic exons produced transcript variants that generated de novo proteins. We found that the inclusion of cryptic peptide sequences in proteins altered their interactions with other proteins, thereby likely altering their function. Last, we showed that 18 de novo peptides across 13 genes were present in CSF samples from patients with ALS/FTD spectrum disorders. The demonstration of cryptic exon translation suggests new mechanisms for ALS/FTD pathophysiology downstream of TDP-43 dysfunction and may provide a potential strategy to assay TDP-43 function in patient CSF.
Type III Internal Hemipelvectomy with Soft Tissue Reconstruction: A 20 Year Study of Surgical and Functional Outcomes
Salinas, Cristina A., Mullen, Barbara , Broida, Samuel, Moran, Steven L. , Willborg, Brooke E. , Rode, Matthew M. , Houdek, Matthew T.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 25, 2024 | Volume: 12 | Issue: 1S1 | Pages: 39-39

10.1097/01.gox.0001006052.22252.c4 Get It

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
Bantilan, Kurt S. , Smith, Alexandra N., Maurer, Matthew J. , Teruya‐Feldstein, Julie , Matasar, Matthew J. , Moskowitz, Alison J. , Straus, David J. , Noy, Ariela , Palomba, M. Lia , Horwitz, Steven M. , Portlock, Carol S., Nowakowski, Grzegorz S. , Moskowitz, Craig H. , Hamlin, Paul A , Cerhan, James R , Salles, Gilles A , Nowakowski, Grzegorz S , Zelenetz, Andrew D , Maurer, Matthew , Horwitz, Steven M , Matasar, Matthew , Noy, Ariela , Cerhan, James R. , Habermann, Thomas M. , Salles, Gilles , Zelenetz, Andrew D.

Mayo Clinic

Blood Advances | January 25, 2024 | Volume: 8 | Issue: 9 | Pages: 2172-2181

10.1182/bloodadvances.2023011408 | PMID 38271621 Get It

Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered the standard-of-care for patients with advanced-stage diffuse large B-cell lymphoma (DLBCL), despite findings that patients with nongerminal center B-cell like (non-GCB) have significantly worse outcome with this regimen. We evaluated the prognostic significance of baseline risk factors, including cell of origin (COO) classified by the Hans algorithm, within an alternative chemoimmunotherapy program. At Memorial Sloan Kettering Cancer Center (MSK), 151 patients with DLBCL received sequential R-CHOP induction and (R)-ICE (rituximab, ifosfamide, carboplatin, and etoposide) consolidation. Outcome analysis based on COO was validated with a propensity score–matched cohort treated with R-CHOP from the Mayo Clinic component of the Molecular Epidemiology Resource (MER). Among the patients with GCB (n = 69) and non-GCB (n = 69) at MSK, event-free survival (EFS) of non-GCB was superior to that of GCB (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.29-0.98). Overall survival (OS) demonstrated an association in the same direction but was not statistically significant (HR, 0.68; 95% CI, 0.33-1.42). Propensity score–matched patients from MSK (n = 108) demonstrated a small attenuation in the HRs for EFS (HR, 0.57; 95% CI, 0.27-1.18) and OS (HR, 0.76; 95% CI, 0.33-1.79) and were no longer statistically significant. In contrast, the matched MER cohort (n = 108) demonstrated an EFS association (HR, 1.17; 95% CI, 0.70-1.95) and OS association (HR, 1.13; 95% CI, 0.64-2.00) in the opposite direction, but were also not statistically significant. R-CHOP induction and (R)-ICE consolidation may overcome the negative prognostic impact of the non-GCB phenotype, per the Hans algorithm, and can be preferentially selected for this population. This trial was registered at www.ClinicalTrials.gov as #NCT00039195 and #NCT00712582.
Clinical Images: Sarcoidosis with concomitant aortitis and coronary arteritis
Kaymakci, Mahmut , Araoz, Philip A. , Koster, Matthew J. , Elfishawi, Mohanad M, Kaymakci, Mahmut S , Koster, Matthew J , Elfishawi, Mohanad , Lo, Ying‐Chun , Warrington, Kenneth J.

Mayo Clinic

ACR Open Rheumatology | January 25, 2024 | Volume: 6 | Issue: 4 | Pages: 201-202

10.1002/acr2.11631 | PMID 38269608 Get It

Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy Using Artificial Intelligence
Khanna, Abhinav, Antolin, Alenka, Bar, Omri , Ben-Ayoun, Danielle, Zohar, Maya, Boorjian, Stephen A. , Frank, Igor, Shah, Paras , Sharma, Vidit , Thompson, R. Houston, Wolf, Tamir, Asselmann, Dotan, Tollefson, Matthew K. , Tollefson, Matthew

Mayo Clinic

Journal of Urology | January 24, 2024 | Volume: 211 | Issue: 4 | Pages: 575-584

10.1097/ju.0000000000003845 | PMID 38265365 Get It

Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals
Jack, Clifford R. , Wiste, Heather J. , Weigand, Stephen D. , Lowe, Val J. , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Fields, Julie A. , Therneau, Terry M. , Petersen, Ronald C. , Figdore, Dan J, Jack, Clifford R , Vemuri, Prashanthi , Algeciras‐Schimnich, Alicia , Figdore, Daniel J. , Ramanan, Vijay K. , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Schwarz, Christopher G. , Cogswell, Petrice M. , Senjem, Matthew L.

Mayo Clinic

Alzheimer's & Dementia | January 24, 2024 | Volume: 20 | Issue: 3 | Pages: 2143-2154

10.1002/alz.13651 | PMID 38265198 Get It

Abstract BACKGROUND We compared the ability of several plasma biomarkers versus amyloid positron emission tomography (PET) to predict rates of memory decline among cognitively unimpaired individuals. METHODS We studied 645 Mayo Clinic Study of Aging participants. Predictor variables were age, sex, education, apolipoprotein E ( APOE ) ε 4 genotype, amyloid PET, and plasma amyloid beta (Aβ)42/40, phosphorylated tau (p‐tau)181, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and p‐tau217. The outcome was a change in a memory composite measure. RESULTS All plasma biomarkers, except NfL, were associated with mean memory decline in models with individual biomarkers. However, amyloid PET and plasma p‐tau217, along with age, were key variables independently associated with mean memory decline in models combining all predictors. Confidence intervals were narrow for estimates of population mean prediction, but person‐level prediction intervals were wide. DISCUSSION Plasma p‐tau217 and amyloid PET provide useful information about predicting rates of future cognitive decline in cognitively unimpaired individuals at the population mean level, but not at the individual person level.
Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
Jones, Robin L. , Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le, Davis, Erika, Achour, Haroun, Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , investigators, on behalf of the INTRIGUE study, Jones, Robin L , Zalcberg, John , Blay, Jean‐Yves , George, Suzanne , Gelderblom, Hans , Mehren, Margaret von , Kang, Yoon‐Koo , Trent, Jonathan C. , Cesne, Axel Le , Bauer, Sebastian , Heinrich, Michael C. , investigators, on behalf of the INTRIGUE study

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 748-748

10.1200/jco.2024.42.3_suppl.748 Get It

748 Background: Ripretinib is a switch-control tyrosine kinase inhibitor approved for patients (pts) with gastrointestinal stromal tumor (GIST) who received prior treatment with 3 or more kinase inhibitors, including imatinib. Sunitinib is approved for advanced GIST after imatinib failure. In the second interim analysis of overall survival (OS) from the phase 3 INTRIGUE study, the OS event rate was 41% in the all-patient (AP) intent-to-treat (ITT) population, and OS was similar between treatment arms in both the KIT exon 11 ITT and AP ITT populations. Here, we present the final OS and updated safety from INTRIGUE. Methods: INTRIGUE (NCT03673501) is an open-label, phase 3 study of adults with advanced GIST who had disease progression on or intolerance to imatinib. Randomization was 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 weeks on/2 weeks off) and was stratified by KIT mutational status and imatinib intolerance. OS was a key secondary endpoint (the primary endpoint of progression-free survival was reported previously); final OS analysis was prespecified to occur with ≥200 and ≥145 events in the AP ITT and KIT exon 11 ITT populations, respectively. Data cutoff was March 15, 2023. Results: Of 453 pts, 444 received treatment; 40 remain on treatment (ripretinib, 28/223 [13%]; sunitinib, 12/221 [5%]). Treatment discontinuation was due to progressive disease (PD) by independent radiologic review (56%), PD by investigator (11%), clinical PD (6%), withdrawal of consent (6%), and adverse events (AEs; 5%). Fewer pts discontinued treatment due to AEs with ripretinib vs sunitinib (3% vs 6%). There were 211 OS events (47%) in the AP ITT population and 151 OS events (46%) in the KIT exon 11 ITT population. OS was similar with ripretinib vs sunitinib in the 2 ITT populations (Table). Fewer pts had grade 3/4 treatment-emergent AEs with ripretinib vs sunitinib (43% vs 67%). Dose interruptions and reductions were lower with ripretinib vs sunitinib. Median treatment duration for ripretinib vs sunitinib was 7.9 vs 6.5 months. Conclusions: In the finalOS analysis from the INTRIGUE study, OS was similar between treatment arms. The safety profile remained consistent and more favorable for ripretinib vs sunitinib in pts with advanced GIST previously treated with imatinib. Clinical trial information: NCT03673501 . [Table: see text]